Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Polynovo ( (AU:PNV) ) has shared an announcement.
Polynovo’s recent announcement highlights the capabilities of its NovoSorb matrix in promoting regenerative healing by organizing large wounds into smaller ones, which the body can heal more effectively. This advancement is expected to enhance the company’s market position in the regenerative medicine sector, potentially benefiting stakeholders by improving patient outcomes and expanding market reach.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
Polynovo operates in the medical technology industry, focusing on regenerative healing solutions. Its primary product, NovoSorb, is designed to facilitate organized and regenerative healing of large wounds by transforming them into smaller, more manageable wounds.
YTD Price Performance: -46.08%
Average Trading Volume: 2,086,632
Technical Sentiment Signal: Sell
Current Market Cap: A$759.9M
Learn more about PNV stock on TipRanks’ Stock Analysis page.